{"filings":[{"id":92505,"accession_number":"0001376339-26-000032","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MiMedx Q1 net sales $59M (-33% YoY), loss $11M; cuts FY guidance to $260-290M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net sales $59M, down 33% YoY from $88M; net loss $11M vs net income $7M a year ago.","Surgical product sales up 13% YoY; Wound sales down 60% due to Medicare payment cap per cm².","Gross margin fell to 71% from 81% on pricing pressure and unfavorable product mix.","FY2026 net sales guidance lowered to $260-290M; Adjusted EBITDA expected approximately breakeven.","Company plans $40M annualized cost savings; CEO targets return to profitability in H2 and double-digit growth in 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":58991000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92504,"accession_number":"0001376339-26-000021","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"MiMedx Announces Restructuring and $40M Annual Cost Reduction Initiative","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Eliminated Chief Operating Officer position held by Ricci Whitlow; her departure effective immediately.","CEO Joe Capper's base salary reduced by 20%; other named executive officers receive 10% salary reductions through Dec 31, 2026.","Company expects annualized savings of approximately $40 million; expects one-time restructuring charge of ~$4 million in Q2 2026.","Cost reduction due to slower-than-expected recovery in Wound Care business following January 1 Medicare reimbursement cut.","Surgical business continues to grow and warrants additional investments; restructuring to streamline operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103383,"accession_number":"0001376339-26-000012","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MiMedx posts record Q4 sales $118M (+27% YoY); 2026 guidance $340-360M; $100M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $118M, +27% YoY; full-year $419M, +20% YoY.","Q4 GAAP net income $15M ($0.10 EPS); Adjusted EBITDA $29M (25% margin).","2026 net sales guidance $340-360M, down from 2025 actual; Adj EBITDA margin mid-to-high teens.","Board authorizes $100M share repurchase program over two years.","Cash & equivalents $166M; net cash $148M; SG&A up 18% to $266M on higher commissions."],"consensus_eps_estimate":null,"consensus_eps_actual":0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":418630000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103382,"accession_number":"0001376339-26-000003","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MiMedx updates investor presentation on January 12, 2026; no specific data available","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["MiMedx updated its investor slide presentation on January 12, 2026.","Only a disclaimer header is visible in the furnished exhibit; presentation content not provided.","No financial results, guidance, or material changes are disclosed in the filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119624,"accession_number":"0001376339-25-000104","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MiMedx Q3 record revenue $114M (+35% YoY); raises FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net sales $114M, up 35% YoY; GAAP net income $17M, diluted EPS $0.11.","Adjusted EBITDA $35M, 31% of net sales; Wound product sales grew 40%, Surgical 26%.","Cash and equivalents $142M at Sept 30, up from $104M at Dec 31, 2024.","2025 outlook raised: net sales growth mid-to-high teens, adjusted EBITDA margin at least mid-20%.","CEO cites record revenue, cash flow; awaiting final 2026 CMS reimbursement rules."],"consensus_eps_estimate":null,"consensus_eps_actual":0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":300535000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136197,"accession_number":"0001376339-25-000093","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MiMedx updates investor deck for Cantor conference; no specific new metrics revealed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company to participate in Cantor Global Healthcare Conference on September 3, 2025.","Updated investor slide presentation furnished as Exhibit 99.1.","Presentation includes forward-looking statements and risk factors; no financial guidance changes disclosed.","Exhibit text provided is incomplete; no specific operational or financial figures available."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136196,"accession_number":"0001376339-25-000087","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MiMedX Q2 net sales $99M record, up 13% YoY; raises 2025 growth to low double-digits","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $99M (record), +13% YoY; GAAP net income $10M ($0.06 EPS); prior year included $9.3M settlement benefit.","Adjusted EBITDA $24M (25% margin); cash $119M, up $15M from Dec 2024.","Wound sales +12%, Surgical +15% YoY; driven by new products CELERA, EMERGE, HELIOGEN.","Raises 2025 net sales growth outlook to low double-digits; reaffirms adjusted EBITDA margin above 20%.","CEO supports CMS proposal to overhaul skin substitute reimbursement; engaging in comment period."],"consensus_eps_estimate":null,"consensus_eps_actual":0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":186810000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153274,"accession_number":"0001376339-25-000059","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MiMedx shareholders re-elect nine directors and approve executive compensation at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders re-elected all nine director nominees including M. Kathleen Behrens, Joseph H. Capper, and William A. Hawkins.","Advisory resolution on executive compensation approved with 94.8 million votes for and 6.9 million against.","Ratification of Deloitte & Touche as independent auditor for fiscal 2025 approved with 123.7 million votes for.","Amendment of the 2016 Equity and Cash Incentive Plan approved with 91.4 million votes for.","Shareholders voted for an annual frequency of say-on-pay votes (97.5 million for one year)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153273,"accession_number":"0001376339-25-000053","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MiMedx updates investor presentation for BofA healthcare conference on May 13, 2025","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company participated in BofA Securities 2025 Healthcare Conference on May 13, 2025.","Filed updated investor slide deck as Exhibit 99.1; full presentation content not provided in this filing extract.","No specific financial or strategic updates are identifiable from the limited exhibit text available.","Routine FD disclosure; no forward-looking guidance or material changes were disclosed in the 8-K body.","Investors should review the complete presentation for any new information."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153272,"accession_number":"0001376339-25-000044","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MiMedx Q1 net sales $88M (+4% YoY); GAAP EPS $0.05; reaffirms high single-digit growth outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $88M (+4% YoY); GAAP net income $7M ($0.05 EPS); Adj. EBITDA $17M (20% margin).","Gross margin fell to 81% from 85% on product mix; Surgical products grew 16%, Wound fell 2%.","Cash $106M; net debt $0; 2025 outlook: high single-digit sales growth and >20% Adj. EBITDA margin.","CEO calls LCD delay disappointing; added CELERA product as contingency for affected settings.","SG&A rose to $60M from $55M on higher commissions, salaries, and legal/regulatory costs."],"consensus_eps_estimate":null,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":88205000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172043,"accession_number":"0001376339-25-000013","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MiMedx updates investor presentation; specific content not available in filing excerpt","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Investor presentation dated February 27, 2025, furnished under Regulation FD.","No financial targets, guidance changes, or operational metrics disclosed in the provided text.","Full slide deck is not included in the excerpt; investors should seek the complete presentation for details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172042,"accession_number":"0001376339-25-000011","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MiMedx Q4 net sales $93M (+7% YoY), Adjusted EBITDA margin 21%, guides high-single-digit growth for 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 net sales $93M (+7% YoY); full year $349M (+9% YoY). Adjusted EBITDA margin 21% for Q4.","GAAP net income Q4 $7M ($0.05 EPS); full year $42M. Cash $104M at Dec 31, net cash $86M.","2025 outlook: net sales growth at least high single-digits, Adjusted EBITDA margin above 20%.","SG&A increased to $61M in Q4 from $54M a year ago; CEO cites Medicare disruption but remains confident."],"consensus_eps_estimate":null,"consensus_eps_actual":0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":348879000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172041,"accession_number":"0001193125-25-005766","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MiMedx updates investor presentation; no material changes disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Investor presentation updated on January 14, 2025.","No specific financial, operational, or strategic updates provided in the filing.","Presentation content not fully available; confidence in material impact low."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189036,"accession_number":"0001193125-24-279618","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"MiMedx extends HQ lease through July 2029 and adopts director/officer indemnification agreements","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease with CPVF II West Oak LLC extended from July 31, 2026 to July 31, 2029; two optional two-year extensions added.","Amendment provides tenant improvement funds from landlord and modifies rent terms; headquarters remains in Marietta, GA.","Board approved form of Indemnification Agreement for all directors and executive officers to fullest extent under Florida law.","Indemnification agreements cover expenses, advancements, and procedures for claims arising from service to company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189035,"accession_number":"0001193125-24-260490","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MiMedx Group presents at two investor conferences; slide deck furnished","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Senior management to present at Stifel 2024 Healthcare Conference on Nov 18 and Craig-Hallum Capital Group 15th Annual Alpha Select Conference on Nov 19.","Slide presentation furnished as Exhibit 99.1; no specific financial or operational updates are included in the 8-K filing text.","The exhibit content is not fully provided in this excerpt, so no material new information from the slides can be summarized.","This is a routine Regulation FD disclosure with no new earnings, guidance, or corporate actions announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189034,"accession_number":"0001193125-24-247640","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MiMedx Q3 net sales $84M (+3% YoY); raises FY2024 growth outlook to high single-digits","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $8.1M ($0.05 EPS); Adjusted EBITDA $18.2M (21.6% margin), up from $17.6M a year ago.","Cash and cash equivalents $89M; net cash position $70M, up $20M sequentially.","2024 net sales growth guidance raised to high single-digits (from mid-to-high single-digits); Adjusted EBITDA margin expected above 20%.","Q3 gross margin 81.8% vs 81.9% prior year; growth driven by AMNIOEFFECT, EPIEFFECT and HELIOGEN products."],"consensus_eps_estimate":null,"consensus_eps_actual":0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":255972000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205515,"accession_number":"0001193125-24-189932","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MiMedx Q2 revenue $87M (+7% YoY), GAAP EPS $0.12, Adjusted EBITDA margin 23%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $87M, up 7% YoY; GAAP net income $18M, EPS $0.12.","Adjusted EBITDA $20M, margin 23% vs 17.4% in Q2 2023.","CEO reports competitive pressure from high-priced skin substitutes causing employee and customer attrition.","Launched HELIOGEN (first xenograft) and commenced RCT for EPIEFFECT.","Cash $69M; 2024 net sales growth guided to mid-to-high single digits."],"consensus_eps_estimate":null,"consensus_eps_actual":0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":171915000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222444,"accession_number":"0001376339-24-000055","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MiMedx shareholders re-elect all nine directors, approve say-on-pay at AGM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["80.74% of shares represented; all nine director nominees re-elected with substantial votes for (over 88M each).","Advisory say-on-pay resolution passed with 68.7M for, 24.0M against, 1.1M abstentions.","Ratification of Deloitte & Touche as auditor for FY2024 approved with 116.7M for, 2.3M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222443,"accession_number":"0001193125-24-125073","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MiMedx Q1 net sales $85M (+18% YoY); GAAP net income $9M; Adj. EBITDA $19M (22% margin)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $85M, up 18% YoY; gross margin improved to 84.7% from 82.7%.","GAAP net income $9M vs loss of $5M in prior year; Adjusted EBITDA $19M (22% margin) vs $5.5M (7.7%).","Cash $48M at March 31, down from $82M at Dec 31, due to repaying $30M revolver and $5M TELA Bio payment.","Signed distribution agreement with Regenity Biosciences for 510(k)-cleared collagen xenograft; launch expected later in 2024.","Appointed two new independent directors; launched MIMEDX Connect online ordering platform."],"consensus_eps_estimate":null,"consensus_eps_actual":0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":84709000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}